C R Bard Inc (BCR) Receives $290.20 Average Price Target from Analysts

C R Bard Inc (NYSE:BCR) has been assigned an average recommendation of “Hold” from the twelve research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $290.20.

A number of research firms recently weighed in on BCR. BidaskClub raised shares of C R Bard from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 8th. Cowen and Company reissued a “hold” rating and set a $317.00 price target on shares of C R Bard in a research note on Friday. Zacks Investment Research downgraded shares of C R Bard from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Needham & Company LLC reissued a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $317.00 price target on shares of C R Bard in a research note on Thursday, September 14th.

WARNING: “C R Bard Inc (BCR) Receives $290.20 Average Price Target from Analysts” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://stocknewstimes.com/2017/11/21/c-r-bard-inc-bcr-receives-290-20-average-price-target-from-analysts.html.

C R Bard (NYSE:BCR) traded down $1.71 on Thursday, hitting $333.86. 620,597 shares of the company were exchanged, compared to its average volume of 478,414. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. The company has a market capitalization of $24,335.72, a P/E ratio of 28.83, a price-to-earnings-growth ratio of 2.55 and a beta of 0.53. C R Bard has a twelve month low of $203.63 and a twelve month high of $335.84.

C R Bard (NYSE:BCR) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C R Bard had a net margin of 9.51% and a return on equity of 19.39%. C R Bard’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.64 earnings per share. equities analysts anticipate that C R Bard will post 11.89 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date is Thursday, December 7th. C R Bard’s dividend payout ratio is currently 13.70%.

In related news, Director David M. Barrett sold 3,344 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $327.31, for a total transaction of $1,094,524.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Betty D. Larson sold 5,906 shares of the business’s stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $330.16, for a total transaction of $1,949,924.96. Following the transaction, the vice president now owns 10,753 shares of the company’s stock, valued at approximately $3,550,210.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 136,568 shares of company stock valued at $43,932,079. Corporate insiders own 0.80% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA boosted its holdings in shares of C R Bard by 75.8% in the third quarter. BNP Paribas Arbitrage SA now owns 353,485 shares of the medical instruments supplier’s stock valued at $113,292,000 after buying an additional 152,468 shares during the period. Global X MANAGEMENT CO LLC boosted its holdings in shares of C R Bard by 11.6% in the third quarter. Global X MANAGEMENT CO LLC now owns 1,821 shares of the medical instruments supplier’s stock valued at $584,000 after buying an additional 189 shares during the period. Candriam Luxembourg S.C.A. boosted its holdings in shares of C R Bard by 3.3% in the third quarter. Candriam Luxembourg S.C.A. now owns 4,901 shares of the medical instruments supplier’s stock valued at $1,571,000 after buying an additional 156 shares during the period. Swiss National Bank boosted its holdings in shares of C R Bard by 7.2% in the third quarter. Swiss National Bank now owns 282,061 shares of the medical instruments supplier’s stock valued at $90,401,000 after buying an additional 18,900 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its holdings in shares of C R Bard by 232.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 25,647 shares of the medical instruments supplier’s stock valued at $8,220,000 after buying an additional 17,938 shares during the period. Institutional investors own 79.27% of the company’s stock.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply